BRPI0913939A2 - dose unitária de apadenoson - Google Patents

dose unitária de apadenoson

Info

Publication number
BRPI0913939A2
BRPI0913939A2 BRPI0913939A BRPI0913939A BRPI0913939A2 BR PI0913939 A2 BRPI0913939 A2 BR PI0913939A2 BR PI0913939 A BRPI0913939 A BR PI0913939A BR PI0913939 A BRPI0913939 A BR PI0913939A BR PI0913939 A2 BRPI0913939 A2 BR PI0913939A2
Authority
BR
Brazil
Prior art keywords
apadenoson
unit dose
dose
unit
Prior art date
Application number
BRPI0913939A
Other languages
English (en)
Inventor
Robert Hendel
Shannon P Williams
William B Stilley
Original Assignee
Univ Virginia Patent Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia Patent Found filed Critical Univ Virginia Patent Found
Publication of BRPI0913939A2 publication Critical patent/BRPI0913939A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BRPI0913939A 2008-07-03 2009-07-02 dose unitária de apadenoson BRPI0913939A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7816908P 2008-07-03 2008-07-03
US15593709P 2009-02-27 2009-02-27
PCT/US2009/003939 WO2010002473A1 (en) 2008-07-03 2009-07-02 Unit dosage of apadenoson

Publications (1)

Publication Number Publication Date
BRPI0913939A2 true BRPI0913939A2 (pt) 2016-04-26

Family

ID=41152021

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0913939A BRPI0913939A2 (pt) 2008-07-03 2009-07-02 dose unitária de apadenoson

Country Status (24)

Country Link
US (6) US20100003193A1 (pt)
EP (1) EP2306971B1 (pt)
JP (2) JP2011526894A (pt)
KR (2) KR20110028531A (pt)
CN (1) CN102119023B (pt)
AU (1) AU2009266317B2 (pt)
BR (1) BRPI0913939A2 (pt)
CA (1) CA2729819C (pt)
CY (1) CY1116283T1 (pt)
DK (1) DK2306971T3 (pt)
EA (1) EA022348B1 (pt)
ES (1) ES2537069T3 (pt)
HK (1) HK1156250A1 (pt)
HR (1) HRP20150454T1 (pt)
IL (2) IL210428A (pt)
MX (1) MX2011000193A (pt)
MY (1) MY161655A (pt)
NZ (1) NZ590489A (pt)
PL (1) PL2306971T3 (pt)
PT (1) PT2306971E (pt)
SI (1) SI2306971T1 (pt)
SM (1) SMT201500123B (pt)
WO (1) WO2010002473A1 (pt)
ZA (1) ZA201100163B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ590489A (en) 2008-07-03 2013-01-25 Univ Virginia Patent Found Unit dosage of apadenoson
ES2641855T3 (es) 2012-02-03 2017-11-14 Adenobio N.V. Un método de uso de adenosina y dipiridamol para prueba de esfuerzo farmacológica con composiciones específicas, formas de dosificación unitarias y kits
CN109020881B (zh) * 2018-06-28 2020-04-28 新发药业有限公司 一种阿帕替尼的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091171B2 (en) 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
EP0443827B1 (en) * 1990-02-21 1996-07-17 Her Majesty The Queen In Right Of New Zealand Rare earth substituted thallium-based superconductors
IT1263831B (it) 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
CZ296404B6 (cs) * 1999-02-01 2006-03-15 University Of Virginia Patent Foundation 2-Alkynyladenosinové deriváty
US6322771B1 (en) * 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
CN1225570C (zh) * 2000-10-23 2005-11-02 独立行政法人产业技术综合研究所 复合构成物及其制作方法和制作装置
US6620645B2 (en) * 2000-11-16 2003-09-16 G.T. Equipment Technologies, Inc Making and connecting bus bars on solar cells
AU2002362443B2 (en) 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
DE60309847T2 (de) * 2002-02-27 2007-10-18 Ferring B.V. Zwischenprodukte und verfahren zur herstellung von heptapeptid-oxytocinanaloga
JP2006515829A (ja) * 2002-04-10 2006-06-08 ユニバーシティ オブ バージニア パテント ファウンデーション 炎症性疾病の処置のための、a2aアデノシン受容体アゴニストの使用
US6662088B1 (en) * 2002-06-28 2003-12-09 General Electric Company Methods and systems for inspecting aircraft fuselage frames
EP1746885A4 (en) * 2004-05-03 2010-09-08 Univ Virginia ADENOSINE A2A RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETIC NEPHROPATHY
NZ585697A (en) 2004-08-02 2011-12-22 Univ Virginia Patent Found 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
DE602005011111D1 (de) 2005-06-03 2009-01-02 St Microelectronics Srl Selbstjustiertes Verfahren zur Herstellung von Phasenwechselspeicherzellen
US7767686B2 (en) 2006-03-03 2010-08-03 Covidien Ag Method of using adenosine receptor blockers during tissue ablation
DE102006022450A1 (de) 2006-05-13 2007-11-15 Lanxess Deutschland Gmbh Wässrige Rußdispersionen für Ink-Jet
CA2694983A1 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Treatments of b-cell proliferative disorders
TW200905703A (en) * 2007-07-27 2009-02-01 Delta Electronics Inc Magnetic device and manufacturing method thereof
NZ590489A (en) 2008-07-03 2013-01-25 Univ Virginia Patent Found Unit dosage of apadenoson

Also Published As

Publication number Publication date
EA201100132A1 (ru) 2011-08-30
IL210428A (en) 2016-05-31
AU2009266317A1 (en) 2010-01-07
US20100003193A1 (en) 2010-01-07
US9662406B2 (en) 2017-05-30
US20190022253A1 (en) 2019-01-24
WO2010002473A1 (en) 2010-01-07
MX2011000193A (es) 2011-03-24
JP2011526894A (ja) 2011-10-20
CY1116283T1 (el) 2017-02-08
PL2306971T3 (pl) 2015-07-31
AU2009266317B2 (en) 2013-12-05
IL245577A0 (en) 2016-06-30
CN102119023A (zh) 2011-07-06
MY161655A (en) 2017-04-28
PT2306971E (pt) 2015-06-18
ZA201100163B (en) 2011-09-28
IL245577B (en) 2019-05-30
ES2537069T3 (es) 2015-06-02
EP2306971B1 (en) 2015-02-25
CA2729819C (en) 2014-08-26
DK2306971T3 (en) 2015-05-11
EP2306971A1 (en) 2011-04-13
CA2729819A1 (en) 2010-01-07
US20170007722A1 (en) 2017-01-12
EA022348B1 (ru) 2015-12-30
KR20110028531A (ko) 2011-03-18
US20130017153A1 (en) 2013-01-17
US20140100185A1 (en) 2014-04-10
SI2306971T1 (sl) 2015-07-31
SMT201500123B (it) 2015-09-07
KR20140021726A (ko) 2014-02-20
NZ590489A (en) 2013-01-25
CN102119023B (zh) 2014-04-09
JP2013237702A (ja) 2013-11-28
US20170252463A1 (en) 2017-09-07
HK1156250A1 (en) 2012-06-08
US9415058B2 (en) 2016-08-16
HRP20150454T1 (hr) 2015-06-19
IL210428A0 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
SMT201500186B (it) Autoanticorpi umani anti-alfa-sinucleina
BRPI1011587A2 (pt) compostos e composições terapèuticas
BRPI0920521A2 (pt) combinação farmacêutica
BRPI0916931A2 (pt) agentes terapêuticos
BRPI0906366A2 (pt) Inalador
BRPI1005525A2 (pt) compostos de azaazuleno
DK2326651T3 (da) Buprenorphinanaloger
BRPI0914817A2 (pt) inalador
DK3300729T3 (da) Terapeutiske sammensætninger indeholdende macitentan
BRPI0906779A2 (pt) Inalador
DK2271618T3 (da) Farmaceutiske forbindelser
BRPI0906367A2 (pt) inalador
BRPI0910931A2 (pt) ciclopentanos substituídos terapêuticos
CU23884B1 (es) Derivados de dibenzotiazepina
BRPI0906369A2 (pt) Inalador
SMT201500123B (it) Dosaggio unitario di apadenoson
BRPI0909764A2 (pt) compostos terapêuticos
BRPI1009199A2 (pt) compostos de pirazinoisoquinolina
BRPI0906879A2 (pt) Compostos terapêuticos
FR2937843B1 (fr) Paravent medical
DK2257548T3 (da) Terapeutiske forbindelser
FI20080378A0 (fi) Parannettu hierontalaite
ES1067096Y (es) Chancla desechable
ITPD20080039U1 (it) Plantare meccano-neuro-stimolatore
UA20620S (uk) Масажер

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL